• Mashup Score: 7

    Use of anakinra – an interleukin-1 receptor antagonist – in patients with acute myocarditis was found to be safe but did not reduce complications, according to findings from the ARAMIS trial presented at ESC Congress 2023. The trial randomized 120 symptomatic patients hospitalized with increased cardiac troponin and acute myocarditis at six centers in France to either a daily subcutaneous dose of anakinra (100 mg) or placebo. The median age of participants was 28 years and nearly 90% were men. Patients

    Tweet Tweets with this article
    • Use of anakinra in patients with acute #myocarditis was found to be safe but did not reduce complications in findings from the ARAMIS trial presented today at #ESCCongress. More: https://t.co/sj57hYpm4N #CardioTwitter https://t.co/wwyjmcrg9w

  • Mashup Score: 2

    We present a case of a 54-year-old gentleman with a history of hypertension and chronic HIV who presented with fever and epigastric pain, found to have elevated troponin-I levels and diffuse ST-segement elevations on ECG without clinical evidence of ischemia concerning for myopericarditis. Initial laboratory findings also included thrombocytopenia and elevated aminotransferases as well as…

    Tweet Tweets with this article
    • A fantastic job by @RzechorzekW writing up this case of a condition that frankly I knew nothing about before it showed up in our CCU @WestchesterMed: #anasplasmosis #myocarditis Lesson: stay away from ticks! @fsgfca https://t.co/5jAgeTCrPe